To monitor the development of diabetic eye disease in Denmark and to evaluate the accessibility and effectiveness of diabetic eye screening programs with focus on interregional variations. Target population: The target population includes all patients diagnosed with diabetes. Denmark (5.5 million inhabitants) has ~320,000 diabetes patients with an annual increase of 27,000 newly diagnosed patients. The Danish Registry of Diabetic Retinopathy (DiaBase) collects data on all diabetes patients aged ≥18 years who attend screening for diabetic eye disease in hospital eye departments and in private ophthalmological practice. In 2014-2015, DiaBase included data collected from 77,968 diabetes patients.
Introduction
Diabetic retinopathy is the most common complication in diabetes. 1, 2 It is a chronic, progressive, potentially sight-threatening disease of the retinal microvasculature that is associated with prolonged hyperglycemia and other conditions linked to diabetes mellitus such as hypertension. 3 The threat to sight is due to either growth of new vessels leading to intraocular hemorrhage and possible retinal detachment with profound sight loss or localized damage to the macula of the eye with loss of central visual acuity.
Grading of diabetic retinopathy is based on visible signs of increasing severity on ophthalmoscopy and on imaging. Diabetic retinopathy is classified as proliferative or nonproliferative (background/preproliferative) retinopathy based on the presence or absence of abnormal new vessels, respectively.
Subgroups of nonproliferative diabetic retinopathy (mild, moderate, preproliferative) reflect increasing severity of the disease, which consequently results in shortening of screening intervals. 4 Nonproliferative diabetic retinopathy is typically managed by optimizing the patient's general health. Treatment of proliferative diabetic retinopathy comprises panretinal photocoagulation. It is hypothesized that this technique reduces the amount of ischemic retina, and thus the production of angiogenic molecules.
Retinopathy affecting the macula is separately described as diabetic maculopathy. Diabetic maculopathy is a leading cause of visual loss in diabetic retinopathy. It usually affects older, noninsulin-dependent diabetes patients. Diabetic maculopathy is divided into three types, based on whether it causes focal, ischemic or diffuse edema, and may include tractional (vitreoretinal) or nontractional (intraretinal) components. 3 The management of diabetic macular edema has advanced significantly with the introduction of anti-VEGF (vascular endothelial growth factor) treatments. 3 However, macular laser treatment still plays a major role in treating noncenter-involving macular edema. 5 Vision loss due to diabetic retinopathy is one of the leading causes of visual loss worldwide and is an important cause of impaired vision and disability in the working-age population. 6, 7, 8 Advanced diabetic eye disease has a negative influence on quality of life. 6 Therefore, eye screening for the diabetes population aims to identify patients with early signs of sight-threatening disease to facilitate efficient treatment and prevent loss of sight.
Aim of database
The Danish Registry of Diabetic Retinopathy (DiaBase) was established to monitor the development of diabetic eye disease in Denmark and to evaluate the accessibility and effectiveness of diabetic eye screening programs with focus on interregional variations. 9 The main aim of the registry is to enable evaluation of quality of care for patients with diabetic eye disease.
Target population
The target population includes all patients diagnosed with diabetes in Denmark. At present, Denmark (5.5 million inhabitants) has ~320,000 diabetes patients with an annual increase of ~27,000 newly diagnosed patients. 10 The prevalence of diabetes in Denmark has more than doubled since 1996 and was 5737 per 100,000 people in 2012. 10 DiaBase contains data on all diabetes patients aged ≥18 years who attend screening for diabetic eye disease in the five regions of Denmark. Eye examination of children with diabetes is recorded in the Children Diabetes Registry (DanDiabKids [children and teenagers with diabetes <18 years old]). In 2011, the Adult Diabetes Registry (adult patients with diabetes from 18 years old), the DiaBase, and the DanDiabKids joined to form the Danish Diabetes Database. 9 DiaBase receives data collected from hospital eye departments and private ophthalmological practices where diabetes patients aged ≥18 years attend diabetic eye screening. In Denmark, diabetes care is managed by both primary care physicians in private practice and hospital-based endocrinologists. Diabetic eye screening for most patients attending their primary care physician is delivered by an ophthalmologist in private practice. Patients being followed in endocrinology departments receive diabetic eye screening in the eye department of the respective hospital. Data from each screening visit are collected and sent electronically to DiaBase. An annual report analyzing diabetes screening data from the previous year is issued every spring by the steering committee. National guidelines, based on international guidelines, 3, 5 determine screening intervals and treatment protocols. 11 of these patients, 57,985 had been screened by ophthalmologists in private practice, whereas 20,291 patients had been screened in hospitals.
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Main variables
Key quality indicators for DiaBase were selected according to international standards for good clinical practice: two process indicators to examine efficiency and three performance indicators to examine outcome 9 (Table 1) . Indicator measurements are based on the collection of data with regard to the following main variables: The data on diabetes type and duration of disease are recorded in The Adult Diabetes Registry.
Follow-up
A DiaBase report containing calculations of the key indicators is published every year. At annual meetings, data issues, interregional variations, and definition of indicators are discussed among representatives from each region.
Descriptive data analysis from DiaBase annual report 2014-2015
Patient classification
DiaBase identifies patients with newly diagnosed maculopathy as "diabetic maculopathy, newly diagnosed". In case of treatment for diabetic eye disease, screening is temporarily discontinued. After completion of treatment, patients re-enter regular diabetic eye screening and are described as "resumed routine screening". 9 Patients with treated diabetic maculopathy are recorded in the category "treated maculopathy, stable". If maculopathy recurs, requiring additional treatment, patients are classified as "treated maculopathy, recurrence". The same system applies to diabetic retinopathy. DiaBase classifies treated patients as "laser-treated proliferative diabetic retinopathy, stable". In case of relapse requiring additional laser treatment, patients are labeled "laser-treated proliferative diabetic retinopathy, recurrence".
Frequency of eye screening
Until 2013, this indicator measured the proportion of diabetes patients who received eye screening at least every 2 years. However, the interval for screening visits should be tailored to the severity of disease. 4, 5 To provide the basis for individualized eye screening intervals, the definition of this indicator was changed to measure the proportion of patients who were screened within the defined time interval (Table 2 ). This ultimately measures access to screening for diabetes patients. Neither hospital eye departments nor ophthalmologists in private practice met the standard for this variable (at least 90% of patients should obtain eye screening within the defined interval). As this is the first year, this indicator is calculated in its altered state, the amount of data collected is still insufficient to provide a proper analysis.
Prevalence of diabetic retinopathy and maculopathy
The nationwide prevalence of nonproliferative diabetic retinopathy is 18%, with 47% of patients screened in hospitals and 14% by ophthalmologists in private practice (Table 3) . Mild nonproliferative diabetic retinopathy alone contributes to 13%, while 78% of diabetes patients do not have diabetic retinopathy. However, there are differences between patients screened in hospitals and by ophthalmologists in private practice. Eighty-six percent of patients screened by ophthalmologists in private practice display no retinopathy, with minor interregional variations. Only 53% of patients screened in hospitals have no diabetic retinopathy, with a wide interregional disparity. These numbers indicate that a higher proportion of patients with more severe diabetes are being treated in hospital departments compared to private ophthalmological practice.
In the Central Denmark Region, 11% of patients screened in hospitals have "proliferative diabetic retinopathy, newly diagnosed", a significantly higher number than in other regions of Denmark. There is less interregional difference if preproliferative patients are included in this category. Even Notes: Numerator: patients whose eye screening was performed within the defined interval ± ~33% of the defined interval (months to next eye screening): 3 months ± 1 month, 6 months ± 2 months, 12 months ± 4 months, 18 months ± 6 months, 24 months ± 8 months, 48 months ± 12 months; denominator: all screening visits were performed in the defined period, where an earlier visit had been recorded and a planned interval defined by the ophthalmologist; unknown: number of months to next screening visit not disclosed.
a Different screening strategies with longer ± tolerances compared with the other regions explain the low numbers.
b Data collection from patients screened in ophthalmological practice started in 2013 and is still being extended to cover all practices. Abbreviation: CI, confidence interval. Diabetic maculopathy is significantly more uncommon than diabetic retinopathy. The overall prevalence of patients without diabetic maculopathy is 97% in the registry (91% screened in hospitals vs 98% screened by ophthalmologists in private practice). Only 2% of all patients have newly diagnosed diabetic maculopathy, and an equally small number of patients have stable maculopathy after treatment (Table 4) . Notes: Numerator: patients whose poorest eye progressed to a more severe stage of diabetic eye disease since the last eye screening visit in the year before the annual report (higher number = more severe stage of disease): 1, none; 2, mild nonproliferative; 3, moderate nonproliferative; 4, preproliferative; 5, treated stable proliferative retinopathy/macular edema; 6, active proliferative retinopathy or diabetic macular edema -treated or recurrence. Denominator: all patients whose poorest eye was not labeled as being in the most severe stage of eye disease previous to the year of the annual report.
a Data collection from patients screened in ophthalmological practice started in 2013 and is still being extended to cover all practices. Abbreviation: CI, confidence interval.
Progression/regression of diabetic retinopathy and maculopathy
Diabetic retinal changes may progress as well as regress, essentially depending on medical treatment and diabetic control. The proportion of diabetes patients progressing to a more severe level of diabetic eye disease is a key outcome measurement for DiaBase (Table 5) . This requires at least two eye screening visits with retinopathy and maculopathy grading. To calculate this indicator, patients with the poorest-seeing eye and in the most severe stage of disease at the first of the screening visits are excluded from the assessment. Furthermore, the proportion of diabetes patients regressing to a milder stage of diabetic eye disease is assessed (Table 6 ). This also requires at least two eye screening visits with retinopathy and maculopathy grading. To calculate this indicator, patients with the poorest-seeing eye and in the mildest stage of disease (none) at the first of the screening visits are excluded from the assessment.
In 2014-2015, 10% of registered patients progressed to a more severe stage of disease nationwide. However, this figure is lower than that reported during 2013-2014 (14%). 9 Five percent of patients screened by ophthalmologists in private practice progress to a more severe disease compared to 15% of patients screened in hospitals. There is a wide interregional variation (12%-22%) in the latter group. 
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Andersen et al Eighteen percent of patients screened in hospitals regress to a milder stage of disease (interregional variation between 12% and 23%). Twenty-four percent of patients screened by ophthalmologists in private practice regressed to a milder stage of disease. Nonetheless, the percentage of these patients is significantly higher in the North Denmark region (58%) than in the other regions, where percentages vary between 19% and 28%. This difference may be based on variations in grading due to region-specific circumstances.
Administrative issues and funding
DiaBase was established by N Andersen in collaboration with The Danish Ophthalmological Society and the Organization of Danish Ophthalmologists in Private Practice, 13 based on the status screening for diabetic retinopathy in Denmark. 14 The registry is led by a steering committee of medical retina specialists representing the five regions of Denmark, the Chairman of the Danish Ophthalmological Society, and the Chairman of the Organization of Danish Ophthalmologists in Private Practice.
Initially, the register was partly funded by Hovedstadens Sygehusfaellesskab (Association of Hospitals in the Capital Region of Denmark). DiaBase is funded and operated by The Danish Clinical Registries (RKKP), which is financed and owned by the five Danish regions.
Conclusion
The systematic collection of data from diabetic eye screening in Denmark is still in the development process. Data analysis from DiaBase's latest annual report (2014) (2015) 11 reveals a decrease in the prevalence of diabetic retinopathy from 26% to 22% compared to the previous report (2013-2014), whereas the number of patients diagnosed with diabetes has increased between 1996 and 2012. 10 Additionally, the proportion of patients with regression (20%) is greater than the proportion of patients with progression (10%) of diabetic retinopathy.
The DiaBase is a useful tool to observe the quality of screening, prevalence, and progression/regression of diabetic eye disease. Thus, it contributes to ensure a high quality of care for diabetes patients in Denmark. Reducing the overall morbidity and mortality associated with diabetes by preventing complications may help to relieve the large economic burden of the disease.
